Using PET to determine treatment response in Hodgkin lymphoma

Peter Johnson

Peter Johnson, MA, MD, FRCP, from the University of Southampton, Southampton, UK, talks about the use of response-adapted therapy for the treatment of Hodgkin lymphoma at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. Prof. Johnson discusses the use of PET in clinical trials to determine the response to treatment in a variety of treatment settings. It was found that interim PET scans can be used to assess modulation of therapy, escalation of treatments for patients whose disease is responding less well and de-escalation of treatments for patients who are responding well to therapy. He explains the challenges associated with using this technique in the future and how information can be best put into practice to achieve effective, individualized treatments.
This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

Share this video